$2.04
-0.01 (-0.49%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LPCN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 5 with posted results
Held by 5 tracked-famous managers (JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 3.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDNCT06979544Change from baseline in HAM-D17 total score compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: LPCN 1154A, Placebo | Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression | 90 | 2026-01-16actual | 2026-02-24 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaNCT04874350Change from baseline in Skeletal Muscle Index in LPCN 1148 treated subjects compared to placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LPCN 1148, Placebo | Liver Cirrhosis, Sarcopenia | 30 | 2023-12-18actual | 2024-03-15 |
| A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialNCT04685993results2024-07-17Safety and Tolerability of LPCN 1144Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LPCN 1144 | NASH - Nonalcoholic Steatohepatitis | 25 | 2022-03-01actual | 2024-07-17 |
| The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic SteatohepatitisNCT04134091results2023-12-14Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo | Nonalcoholic Steatohepatitis (NASH) | 56 | 2021-06-24actual | 2023-12-14 |
| Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal MenNCT03868059results2021-06-10Change in Ambulatory Blood Pressure Monitoring (ABPM)-Measured Average 24-hour Systolic Blood Pressure (SBP)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LPCN 1021 | Hypogonadism, Male | 138 | 2019-02-19actual | 2021-06-10 |
| Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)NCT03242408results2019-09-11Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal RangeOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LPCN 1021 | Hypogonadism, Male | 100 | May 2017actual | 2019-10-23 |
| Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).NCT03242590results2019-09-11Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal RangeOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LPCN 1021 | Hypogonadism, Male | 95 | Mar 2017actual | 2019-10-23 |
| Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismNCT02081300Proportion of LPCN 1021-treated subjects who achieve a total testosterone concentration [Cavg] between 300 - 1140 ng/dL.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Oral testosterone undecanoate, LPCN 1021, Topical testosterone gel 1.62 % | Male Hypogonadism | 315 | May 2015actual | 2017-10-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19